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Abstract 
Male rats were given 10% (w/v) ethanol in drinking fluid during the first week, 15% (w/v) during the second week, 20% (w/v) 
during the third, and 25% (w/v) during the fourth week, at the end of which they were kept on 25% (w/v) ethanol drinking water for 3 
weeks. Some animals were then allowed the withdrawal of ethanol for a period of 2 weeks or 7 weeks. No significant differences were 
seen for the basal and forskolin (FK)-stimulated adenylate cyclase (AC) enzyme activities in the pancreatic acinar membranes of 
ethanol-treated and ethanol withdrawal rats as compared to the control group. Chronic ethanol ingestion resulted in an attenuation of 
somatostatin(SS)-inhibited FK-stimulated AC in rat pancreatic acinar membranes. The ability of the stable GTP analogue 5'-guanylyli- 
midodiphosphate (Gpp[NH]p) to inhibit FK-stimulated AC activity was also decreased inpancreatic acinar membranes from ethanol-treated 
rats. Gpp[NH]p was a much less potent inhibitor of SS binding in the pancreatic acinar membranes from chronic ethanol-treated animals 
than in those from controls, suggesting a change of G i. A significant reduction in the number of 125I-Tyrl t-SS receptors was observed 
after ethanol ingestion, when compared with control values. Two weeks after the replacement of the ethanol solution by water, the ethanol 
effect on the parameters cited above persisted. At week 7 of withdrawal, these parameters reached the level of water controls. Ethanol 
administration did not affect either the number or the affinity of secretin receptors as compared to control values which suggests that the 
change in SS binding is not a non-specific effect. Neither chronic ethanol consumption or withdrawal affected somatostatin-like 
immunoreactivity (SSLI). These results suggest hat the attenuated inhibition of AC by SS in pancreatic acinar membranes from 
ethanol-treated rats and ethanol withdrawal (2 weeks) rats may be caused by decreases in both G i activity and in the number of SS 
receptors. Alternatively, an uncoupling of SS receptors from G i and/or a decrease in the level of functional G i may result in both a 
decrease in apparent Bma x for SS binding and in SS-mediated inhibition of AC. Since SS has been suggested to be an inhibitor of basal 
and cholecystokinin (CCK)- and/or secretin-stimulated xocrine pancreatic secretion, it is tempting to speculate that the impairment of 
the SS receptor/effector system seen in the present study can participate in the increase of basal pancreatic exocrine secretion described 
after chronic ethanol consumption. 
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1. Introduction 
Somatostatin (SS), a tetradecapeptide initially isolated 
from the hypothalamus as an inhibitor of pituitary growth 
hormone secretion [1], functions as a local regulator in the 
pancreas and gut [2]. It has been previously reported that 
pancreatic acini possess pecific binding sites for SS [3-5], 
the binding of which results in the triggering of some 
biological actions in the pancreas [6]. In pancreatic acinar 
cells, SS receptors are coupled to the adenylate cyclase 
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(AC) enzyme system via the guanine nucleotide inhibitory 
prote in  G i [3,4]. The extent of G i modifications is corre- 
lated with the ability of SS to inhibit adenosine 3'-5'-cyclic 
monophosphate (cAMP) formation [5]. Guanine nu- 
cleotides also inhibit SS binding to its receptor [4,5,7]. 
Among its various inhibitory functions [6], SS decreases 
pancreatic exocrine secretion [8,9]. 
Previous studies have shown that ethanol can modify 
the action of various peptide hormones on AC in exocrine 
pancreas [10] and in other tissues [11,12]. Ethanol has also 
recently been suggested to affect G i [13]. Since SS inhibits 
FK-stimulated AC via Gi [5], ethanol consumption may 
modify the SS mechanism of action in the exocrine pan- 
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creas. The goals of this study were to determine if chronic 
ethanol ingestion could alter the ability of SS to inhibit 
FK-stimulated AC in rat pancreatic acinar membranes and 
to explore the possible steps at which these alterations 
might occur. In addition, the effect of withdrawal, at 2 and 
7 weeks after the cessation of ethanol ingestion was also 
studied. We have measured the overall catalytic activity of 
the AC activity using FK, an agent which potently stimu- 
lates the catalytic subunit [14]. Experiments were also 
performed to measure the inhibition of specific 125I-Tyr~I- 
SS binding by the stable GTP analogue, Gpp[NH]p in 
order to determine the integrity of SS receptor binding 
site-G protein interactions. In addition, the density of 
125I-TyrH-SS binding sites and SS-mediated AC activity in 
pancreatic acinar membranes were compared and the so- 
matostatin-like immunoreactivity (SSLI) content in pan- 
creas from control and ethanol-treated rats was determined. 
2. Materials and methods 
2.1. Materials 
Synthetic l l Tyr-SS was purchased from Universal Bio- 
logicals (Cambridge, UK); secretin porcine was from 
Neosystem Laboratoire (Strasbourg, France); carrier-free 
Na125I (IMS 30, 100 mCi/ml) was purchased from the 
Radiochemical Center (Amersham, UK); forskolin, baci- 
tracin, phenylmethylsulphonylfluoride (PMSF), guanosine 
triphosphate (GTP), Gpp[NH]p, 3-isobutyl-l-methyl- 
xantine (IBMX) and bovine serum albumin (BSA) were 
purchased from Sigma (St Louis, MO, USA). The rabbit 
antibody used in the radioimmunoassay technique was 
purchased from the Radiochemical Centre (Amersham, 
UK). This antiserum was raised in rabbits against SS-14 
conjugated to BSA and is specific for SS. Since SS-14 
constitutes the C-terminal portions of both SS-25 and 
SS-28, the antiserum does not distinguish between these 
three forms. The binding of SS-14 to this antibody does 
not depend on an intact disulfide bond in the molecule, 
since breaking of the disulfide bond by reaction with 0.1% 
mercaptoethanol (boiling water bath, 5 min) did not change 
peptide immunoreactivity. Cross-reactivity with other pep- 
tides was less than 0.5%. Cross-reaction with several SS 
analogues demonstrated that neither the N-terminal glycine 
nor the C-terminal cysteine residues are required for anti- 
body binding, suggesting that the antigen site is directed 
towards the central part of the molecule containing the 
tryptophan residue. All other reagents were of the highest 
purity commercially available. 
2.2. Experimental nimals 
Male Sprague-Dawley rats (n = 25) from our own 
colony, weighing 200_ 10 g at the beginning of the 
experiment, were maintained under conditions of automati- 
cally controlled temperature (25 + 1 ° C) and 12 h light/12 
dark cycles (09.00-21.00 h). Animals were fed Purina 
chow (UAR-Panlab, Barcelona, Spain) ad libitum. Co- 
prophagia was avoided by placing wire nets over the cage 
floor. Daily caloric intake was estimated from the specific 
calorific value of the commercial Purina chow used (3200 
cal/kg) and the amount of food consumed by the animals, 
which was determined by daily weighing of offered and 
remaining food. The amount of daily fluid intake was also 
determined by volume difference between the offered and 
remaining liquid, and ethanol calories were estimated as 
7.1 cal/g. Animals were subjected to chronic ethanol 
administration i their drinking fluid as described by Tes- 
tar et al. [15]. Alcohol-treated rats were given 10% (w/v) 
ethanol in drinking fluid for 1 week, 15% (w/v)  ethanol 
during the second week, 20% (w/v)  ethanol during the 
third week and 25% (w/v) ethanol during the fourth week. 
At the end of week 4 the animals were kept on 25% (w/v) 
ethanol in drinking water for 3 weeks. Control rats re- 
ceived no treatment but were handled in the same way as 
the ethanol-treated animals. The effects of withdrawing 
ethanol from chronically treated animals were studied by 
withholding ethanol for 2 and 7 weeks. The pancreas was 
removed and trimmed free of fat, connective tissues, and 
lymph nodes. 
2.3. Blood ethanol evels 
Rats were decapited and blood samples were collected 
from the neck wound into heparinized receptacles for 
immediate plasma separation. Plasma aliquots of 0.5 ml 
were used for determination f ethanol by head space gas 
chromatography as previously described [16], using a 
Perkin-Elmer gas chromatograph (model Sigma 3B) 
equipped with a flame ionization detector, a head-space 
injection device, and a Sigma 15 integrator and recorder. 
2.4. Preparation of rat pancreatic acinar membranes 
Dispersed pancreatic acini were obtained from male 
Wistar rats after enzymatic degradation of the organ with 
0.2 units of collagenase/ml in an oxygenated Krebs-Ringer 
medium as described by Amsterdam et al. [17]. After 
thorough washing by sedimentation, acini were transferred 
to 0.3 M sucrose. In 0.3 M sucrose the acini were homoge- 
nized at 4 ° C by use of a Potter homogenizer following the 
Meldolesi et al. method [18]. After sedimentation at 1500 
× g for 12 min, the homogenized membranes were resus- 
pended in 1.56 M sucrose. This suspension was overlaid 
with 0.3 M sucrose and centrifuged at 105000 × g for 150 
min. The plasma-membrane-enriched fraction collected 
from the interphase was pelleted and stored at -70  ° C. 
2.5. Binding of ~25I-Tyr1CSS 
Tyrl l -ss was radioiodinated by chloramine-T iodina- 
tion according to the method of Greenwood [19]. Separa- 
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tion of iodinated SS from unincorporated iodine was car- 
ried out on a Sephadex G-25 (fine) column equilibrated 
and eluted with 0.1 M ~tcetic acid in BSA (0.1% w/v). 
The specific activity of the radioligand was 600 Ci/mmol. 
Binding of 125I-Tyr11-SS was assayed on pancreatic 
acinar membranes from rats by a modified method [20]. 
Binding of 125I-TyrH-SS to pancreatic acinar membranes 
was carried out in a tolal volume of 250 /xl in 50 mM 
Tris-HC1 buffer (pH 7.4) containing 0.5 mM MgCI 2, 3mM 
NaC1, 0.2 mM CaC12, 0.2% (wt/vol) BSA, 0.5 mg/ml 
bacitracin and 0.3 mg/ml soybean trypsin inhibitor (bind- 
ing buffer). Plasma membranes, at 75 /zg of protein/ml 
were incubated for 90 min at 20 ° C with 35 pM 125I-Tyr11- 
SS in the absence or presence of 0.01-10 nM unlabelled 
SS. Bound and free ligand was separated by centrifugation 
at l l000×g for 4 min at 4 °C in a microcentrifuge. 
Radioactivity in the pellet was measured with a gamma 
scintillation counter. Non-specific binding was estimated 
as membrane-associated radioactivity in the presence of 1 
~M SS and specific binding was calculated as the differ- 
ence between total and non-specific membrane-associated 
radioactivity. The effect,; of Gpp[NH]p on 125I-Tyr11-SS 
binding were determined after addition of a range of 
Gpp[NH]p concentrations (10 -l  1-10 4 M) in the binding 
assay buffer. 
mM Tris/HC1/1% albumin buffer (pH 7.4) containing 0.1 
mg trypsin inhibitor, 0.05 mg bacitracin, [125]secretin (0.1- 
0.5.10 -1° M) and different amounts (10 - l l  M-10 -6 M) 
of unlabelled secretin. Bound and free ligand was sepa- 
rated by centrifugation at 11 000 X g for 4 min at 4 ° C in a 
microcentrifuge. Radioactivity in the pellet was measured 
with a gamma scintillation counter. 
2.8. Adenylate cyclase assay 
AC activity was measured as previously reported [23] 
with minor modifications. Briefly, rat pancreatic acinar 
membranes (0.12 mg protein/ml) were incubated with 1.5 
mM ATP, 5 mM MgSO 4, 1 /xM GTP and ATP-regener- 
ating system (7.5 mg/ml creatine phosphate and 1 mg/ml 
creatine kinase), 1 mM 3-isobutyl-l-methylxantine, 0.1 
mM PMSF, 1 mg/ml bacitracin, 1 mM EDTA, and tested 
substances (10 -9 M SS or 10 -5 M FK) in 0.1 ml of 0.025 
M triethanolamine/HC1 buffer (pH 7.4). After 30 min 
incubation at 30 ° C, the reaction was stopped by heating 
the mixture for 3 min. After refrigeration, 0.2 ml of an 
alumina slurry (0.75 g/ml  in triethanolamine/HCl buffer 
[pH 7.4]) was added and the suspension centrifuged. The 
supernatant was taken for assay of cyclic AMP by the 
method of Gilman [24]. 
2.6. Evaluation of radiolabelled peptide degradation 
To determine the extent of tracer degradation during 
incubation, we measured the ability of preincubated pep- 
tide to bind to fresh pancreatic acinar membranes. Briefly, 
125I-Tyrll-ss (35 pM) was incubated with pancreatic aci- 
nar membranes (75 /zg protein/ml) for 90 min at 20 ° C. 
After this preincubation, aliquots of the medium were 
added to fresh pancreatic acinar membranes and incubated 
for an additional 90 min at 20 ° C. The fraction of the 
added radiolabelled peptide which specifically bound dur- 
ing the second incubation was measured and expressed as 
a percentage of the binding that had been obtained in 
control experiments performed in the absence of pancreatic 
acinar membranes during the preincubation period. 
2.7. Binding of 1251-secretin 
125I-secretin was prepared by a minor modification of 
the method of Chang and Chey [21]. 125I-secretin was 
separated using gel chromatography on Sephadex G- 
15/G-50, fine (7/3, wt/wt), followed by chromatography 
on SP-Sephadex C25. The specific activity of 125I-secretin 
determined with a secretin-specific antiserum was 640-700 
Ci/mmol. 
Binding of 125I-secretin was assayed on pancreatic aci- 
nar membranes from rats by a modified method [22]. The 
standard binding assay consisted of incubating membranes 
(150/xg of protein) at 22 ° C for 30 min in 0.250 ml of 20 
2.9. Tissue extraction and SS radioimmunoassay 
For SSLI measurement, the pancreata were rapidly ho- 
mogenized in 1 ml 2 M acetic acid using a Brinkman 
polytron (setting 5, 30 s). The extracts were boiled for 5 
min in an ice-chilled water-bath, and aliquots (100 /zl) 
were removed for protein determination [25]. The ho- 
mogenates were subsequently centrifuged at 15000 × g 
for 15 min at 4 ° C and the supematant was neutralized with 
2 M NaOH. The extracts were stored at -70°C until 
assay. The SS concentration was determined in tissue 
extracts by a modified radioimmunoassay method [26], 
with a sensitivity limit of 10 pg/ml. Incubation tubes 
prepared in duplicate contained 100 /xl samples of tissue 
extracts or standard solutions of 0-500 pg cyclic SS-14 
diluted in phosphate buffer (0.05 M [pH 7.2] containing 
0.3% BSA, 0.01 M EDTA), 200 /~1 appropriately diluted 
anti-SS serum, 100 /xl freshly prepared ~25I-Tyr11-SS di- 
luted in buffer to give 6000 cpm (equivalent to 5-10 pg), 
in a final volume of 0.8 ml. All reagents as well as the 
assay tubes were kept chilled on ice before their incubation 
for 48 h at 4 ° C. Bound hormone was separated from free 
hormone by the addition of 1 ml dextran-coated charcoal 
(dextran T-70, 0.2% w/v,  Pharmacia, Uppsala, Sweden; 
charcoal: Norit A, 2% w/v  Serva, Feinbiochemica, Hei- 
delberg, Germany). Serial dilution curves for the samples 
were parallel with the standard curve. The intra-assay and 
inter-assay variation coefficients were 6.0 and 8.8% re- 
spectively. 
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2.10. Data analysis 
Binding parameters for SS receptor binding were deter- 
mined by least squares analysis of Scatchard plots [27]. 
Statistical comparisons of all the data were carried out 
with one-way analysis of variance (ANOVA) and the 
Student/Newman-Keuls te t. Means among groups were 
considered significantly different when the P-value was 
less than 0.05. Each individual experiment was performed 
in duplicate. 
3. Results 
Blood ethanol levels at the time that the rats were killed 
were 30.1 + 3.5 mM in chronic ethanol-treated rats and 
after ethanol withdrawal, the blood ethanol disappeared. 
With chronic ethanol administration i the drinking fluid, 
both daily food intake (45.7%) and drinking fluid intake 
decreased (32.6%) with respect to the start of ethanol 
administration, and these values were significantly lower 
than those in control rats. Total energy intake in the 
ethanol-treated group did not differ from that of the control 
group because the progressive increment in ethanol-de- 
rived calories balanced the correlated ecrease in calories 
ingested by these rats. Animal weights were significantly 
reduced in the ethanol-treated group (230 + 4 g) as com- 
pared with control rats (314 _+ 3 g) from the 14th day of 
treatment and this difference remained until the end of the 
chronic study (268 + 7 g vs. 352 _ 6 g). 
No significant differences were seen for either basal or 
FK-stimulated AC activity between control and ethanol- 
treated and ethanol withdrawal (2 weeks) rats (Table 1). It 
should be noted that SS did not modify basal AC activity 
but inhibited FK-stimulated AC activity in all experimental 
groups. In the ethanol-treated and ethanol withdrawal (2 
weeks) rats, the capacity of SS to inhibit FK-stimulated 
AC activity was significantly lower than in the control 
group and returned to control values 7 weeks after ethanol 
withdrawal (Table 1). 
In the presence of FK (10 -5 M), which amplifies basal 
AC activity, increasing concentrations of Gpp[NH]p pro- 
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Fig. 1. Dose-effect curves for 5'-guanylylimidodiphosphate (Gpp[NH]p) 
on forskolin (FK)-stimulated adenylyl cyclase (AC) activity in rat pancre- 
atic acinar membranes from control (O), ethanol-treated (O) and ethanol 
withdrawal (2 weeks ( zx ) and 7 weeks ( [] )) rats. Data are expressed as a 
percentage of FK-stimulated activity (100%) in the absence of Gpp[NH]p. 
The results are given as the mean_S.E.M.: of three determinations 
performed in duplicate. For the sake of clarity, S.E.M. are not represented 
but were always below 10% of the mean values. 
duce an inhibitory effect that has been used by several 
investigators as a measure of G i function in membranes 
prepared from different tissues [28]. Pancreatic acinar 
membranes from control, ethanol-treated and ethanol with- 
drawal rats exhibited Gpp[NH]p-elicited inhibitory effects 
on AC (Fig. 1). However, the inhibition achieved at con- 
centrations of Gpp[NH]p ranging between 10-11 and 10 -6 
M was significantly lower in pancreatic acinar membranes 
from ethanol-treated and ethanol withdrawal (2 weeks) rats 
than in those from control rats. 
The ability of Gpp[NH]p to inhibit binding of 1251- 
Tyrll-SS [4,5,7] was used as a functional assay for G i. 
Gpp[NH]p was a much less potent inhibitor of binding in 
the membranes from ethanol-treated and ethanol with- 
drawal (2 weeks) rats than in those from controls (Fig. 2). 
The 50% inhibitory concentration for Gpp[NH]p was 0.24 
/zM in control rats and 0.50, 0.63 and 0.24 #M in rats 
subjected to chronic ethanol treatment and in rats at 2 and 
7 weeks after ethanol withdrawal, respectively. Chronic 
Table 1 
Effect of somatostatin (SS) (10 -9 M) and forskolin (10 -5 M) on adenylyl cyclase (AC) activity (pmol cAMP/min/  mg protein) in pancreatic acinar 
membranes of control and ethanol-treated rats and ethanol withdrawal (2 and 7 weeks) rats 
Control Ethanol Ethanol withdrawal Ethanol withdrawal 
(2 weeks) (7 weeks) 
Basal activity 13.4 + 0.6 13.0 + 0.9 12.8 5:0.7 13.5 + 0.5 
Basal activity + 10 -9 M SS 11.9 5:0.5 12.1 5:0.7 11.7 5:0.8 11.8 + 0.3 
+ 10 -5 M FK 24.3 + 1.1 25.5 5:1.3 25.9 + 1.5 25.1 5:1.2 
Fold FK stimulation over basal 1.8 + 0.1 1.9 -I- 0.2 2.0 + 0.1 1.8 5:0.3 
10 -5 M FK + 10 -9 M SS 17.1 _ 0.4 21.4 + 0.8 22.0 5:0.9 17.9 + 1.1 
% SS inhibition of FK stimulation 52.3 + 3.7 25.6 + 2,4 * 21.4 5:2.2 * 47.2 5:4.7 
Experiments were performed as described in Section 2. Values represent the mean 5: S.E.M. of five separate xperiments. Statistical comparison versus 
control: * P < 0.05. 
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Fig. 2. Dose-effect curves for 5'-guanylylimidodiphosphate (Gpp[NH]p) 
on the specific binding of [125I]-TyrtCsomatostatin ([J25I]-TyrH-SS 35 
pM) to rat pancreatic acinar membranes from control (O), ethanol-treated 
((3) and ethanol withdrawal (2 weeks (zx) and 7 weeks (t2)) rats. The 
results express the values of a pool of the control groups, since differ- 
ences among them were not found. Each point is the mean of six separate 
experiments, each performed in duplicate. For the sake of clarity, S.E.M. 
are not represented but were always below 9% of the mean values. 
Calculated 50% inhibitory concentration values were 0.24/xM in control 
rats, 0.50 /xM in rats subjected to chronic ethanol administration, and 
0.63 /zM and 0.24 /zM in etha:aol withdrawal rats at 2 and 7 weeks. 
ethanol treatment increased the potency of Gpp[NH]p 
2.08-fold, whereas in ethanol withdrawal rats at 2 weeks 
the potency was increased 2.62-fold. The potency of 
Gpp[NH]p in ethanol withdrawal rats at 7 weeks returned 
to control values. 
The specific binding of  125I-TyrI~-SS to pancreatic aci- 
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Fig. 3. Left panel: Competitive inhibition of [12~I]-TyrlCsomatostatin 
([125I]-TyrH-SS, 35 pM) binding to pancreatic acinar membranes by 
unlabelled somatostatin (SS). The membranes (75 /xg protein/ml) were 
incubated for 90 min at 20 ° C in the presence of 35 pM [125I]-TyrH-SS 
and increasing concentrations of native peptide. Points correspond to 
values for control (O), ethanol-treated ((3) and ethanol withdrawal (2 
weeks (zx ) and 7 weeks ( [] )) rats. Each point is the mean of six separate 
experiments, each performed ia duplicate. The results express the value 
of a pool of the control groups, since the Bma x and the K d values of the 
control groups were not affected. For the sake of clarity, S.E.M.'s are not 
represented but were always below 10% of the mean values. Right panel: 
Scatchard analysis of the same data. 
Table 2 
Effect of chronic ethanol treatment and its withdrawal (2 and 7 weeks) on 
somatostatin-like immunoreactivity (SSLI) concentration i rat pancreas 
and on the equilibrium parameters for somatostatin (SS) binding to rat 
pancreatic acinar membranes 
Groups SS receptors SSLI 
8max Kd 
Control 538+ 18 0.055+0.002 7.69+0.83 
Ethanol 171 +9 * * * 0.061 +0.012 6.28+0.92 
Ethanol withdrawal (2 weeks) 107+9 * * * 0.061 +0.006 6.12-t-0.72 
Ethanol withdrawal (7 weeks) 477+20 0.050+0.062 6.66-1-0.72 
Binding parameters were calculated from Scatchard plot by linear regres- 
sion. Units for SSLI are ng SS per mg protein, units for K d are nM and 
units for Bma x are femtomoles of SS bound per mg of protein. The results 
are represented as the means+S.E.M, of five separate xperiments. 
Statistical comparison versus control: * * * P < 0.001. 
nar membranes was t ime-dependent in all experimental 
groups. An apparent equil ibrium was observed between 60 
and 120 min at 20°C  (data not shown). All  subsequent 
binding experiments were therefore conducted at 20°C  for 
90 min. Peptide degradation was determined to rule out the 
possibil ity of  different SS degrading activities in any of the 
preparations which might have affected the interpretation 
of the results. Membranes from each experimental group 
showed a similar peptide degradation capacity and the 
values varied by no more than 11% among experimental 
groups. 
Competit ive inhibition of  125I-Tyr ' -SS binding by in- 
creasing concentrations of unlabeled SS was performed in 
pancreatic acinar membranes from control and ethanol- 
treated rats (Fig. 3). Chronic ethanol ingestion decreased 
~25-I-Tyr~t-SS binding at all unlabelled SS concentrations. 
Scatchard analysis of  stiochiometric data revealed that 
ethanol decreased maximal binding capacity and did not 
modify the affinity of  SS for its receptors (Table 2). Two 
weeks after replacement of  the ethanol solution by water, 
the effect of ethanol on the parameters cited above per- 
sisted. At week 7 after withdrawal, these parameters 
reached the level of water controls. 
Neither chronic ethanol consumption nor withdrawal 
affected SSLI levels (Table 2). Ethanol administration did 
not affect either the affinity (3.9 + 0.5 vs 3.7 5- 0.6, nM) 
or the number (0.8 + 0.1 vs 0.9 + 0.2, pmol /mg protein) 
of  secretin receptors as compared to control values. 
4. Discussion 
In the present study we have reported, for the first time, 
the effect of chronic ethanol intake on the SSLI  content 
and the SS receptor /e f fector  system in rat pancreatic 
acinar membranes. In the experimental protocol used in 
this study, the percentage of ethanol-derived calories and 
blood ethanol levels were similar to those reported when 
ethanol was given in a l iquid diet [29-32]. Similar concen- 
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trations of ethanol have been detected in the blood of 
humans with severe intoxication [33]. 
The observations of other authors howing that SS does 
not modify basal AC activity [3,34] and that FK stimulates 
rat pancreatic AC activity [35] are confirmed in the present 
study. SS was a partial antagonist of FK-stimulated pan- 
creatic AC activity, in agreement with Heisler [34]. The 
ability of SS to inhibit FK-stimulated AC is dramatically 
attenuated in pancreatic acinar membranes from ethanol- 
treated and ethanol withdrawal (2 weeks) rats compared 
with their controls. However, there did not appear to be 
any defect in the catalytic unit of AC itself since in 
membranes from either control, ethanol-treated and ethanol 
withdrawal (2 weeks) animals, similar levels of activity 
were noted both in basal conditions and when this enzyme 
was directly stimulated by the diterpene FK. 
The inhibitory effect of Gpp[NH]p on FK-stimulated 
AC was markedly decreased in pancreatic acinar mem- 
branes from ethanol-treated and ethanol withdrawal (2 
weeks) rats, which suggests an abnormality at the G i level 
in these membranes that would explain the decreased 
inhibition of AC by SS after ethanol ingestion. These latter 
findings are consistent with data obtained by Bauch6 et al. 
[36] who found that ethanol in vitro was able to abolish the 
AC inhibitory response to the adenosine R i ana log,  N 6- 
phenylisopropyladenosine (N6-PIA). In addition, we exam- 
ined the functional activity of G i by exploring the ability 
of Gpp[NH]p to inhibit binding of 125I-TyrlI-SS to pancre- 
atic acinar membranes [4,5,7]. Gpp[NH]p was a much less 
potent inhibitor of J25I-Tyr11-SS binding to pancreatic 
acinar membranes in ethanol-treated and ethanol with- 
drawal (2 weeks) rats than in control rats. This finding 
suggests that there is a less functional G1 in the ethanol- 
treated rats and provides a mechanism for the decreased 
inhibition of FK-stimulated AC by SS in this condition. 
The SSLI content as well as the binding parameters of
SS receptors in the control rats were similar to those 
previously reported by others [3,4,28]. Within the past two 
years, at least five SS receptor subtypes have been cloned 
[37]. The pancreas appears to express only SSTR2 [38]. 
Since there is a lack of evidence for ethanol metabolism by 
the pancreas [39,40] and the inhibitory effects of ethanol 
on the SS receptor/effector system are reversible, it is 
possible that the inhibitory effects of ethanol on the SS 
mechanism of action are direct. It has been hypothesized 
that the action of ethanol is the result of ethanol-induced 
changes in the fluidity of membranes [41] and that these 
changes in the membrane's physical characteristics would 
influence the function of membrane-bound proteins such 
as receptors [42]. 
It is conceivable that the changes in SS receptor number 
in pancreatic acinar membranes after chronic ethanol con- 
sumption may be due to the derangement in receptor 
biosynthesis. Various studies have led to the conclusion 
that chronic ethanol consumption interferes with genetic 
code transcription and protein synthesis [43]. 
Ethanol administration did not affect either the number 
or the affinity of secretin receptors as compared to control 
values. These results, therefore, suggest that the change in 
SS binding is not a non-specific effect and are consistent 
with a study of Uhlemann et al. [44] who found no changes 
in the number of secretin receptors in pancreatic acini after 
ethanol treatment. 
These results suggest hat the attenuated inhibition of 
AC by SS in pancreatic acinar membranes from ethanol- 
treated and ethanol withdrawal rats may be caused by 
decreases in both G i activity and in the number of SS 
receptors. Alternatively, an uncoupling of SS receptors 
from G i and/or a decrease in the level of functional G i 
may result in both a decrease in the apparent B~a x for SS 
binding and in SS-mediated inhibition of AC. 
In summary, we have demonstrated that the SS recep- 
tor/effector system in pancreatic acinar membranes is 
altered by chronic ethanol consumption and withdrawal (2 
weeks). This impairment may explain, at least partly, the 
increase in pancreatic exocrine secretion observed uring 
chronic ethanol ingestion. 
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